Cencora Signs Deal to Acquire Majority Equity Interest in OneOncology, Updates Outlook

MT Newswires Live12-15 21:22

Cencora (COR) said Monday it has entered into a definitive agreement to acquire a majority of OneOncology's outstanding equity interests it does not already own from TPG (TPG) and other shareholders.

The company said the transaction values OneOncology at about $7.4 billion, including an equity value of about $6 billion, and is expected to close by the end of its fiscal Q2 2026.

Cencora said it will pay about $3.6 billion for the outstanding equity interests and retire $1.3 billion of OneOncology's debt, for a total cash consideration of about $5 billion.

OneOncology's affiliated practices and management will retain a minority interest, the company said.

The company said it plans to fund the acquisition with new debt and prioritize deleveraging while maintaining investment-grade credit ratings.

Cencora said its full year adjusted diluted EPS will now likely be toward the lower half of its outlook range of $17.45 to $17.75.

The company raised its long-term guidance to reflect the expected contribution from OneOncology, increasing its adjusted diluted EPS growth outlook to 10% to 14%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment